Pharmacogenomics of nicotinic acid with laropiprant in Hong Kong Chinese patients with dyslipidemia.
Phase of Trial: Phase IV
Latest Information Update: 28 Apr 2016
At a glance
- Drugs Niacin/laropiprant (Primary)
- Indications Dyslipidaemias; Hypercholesterolaemia
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 27 Apr 2016 Status changed from recruiting to completed.
- 13 Apr 2012 Status changed from not yet recruiting to recruiting as reported by Chinese Clinical Trial Register record.
- 21 Oct 2010 New trial record